Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum Authors: Sebastian Riemann, Imke Matthys, Tania Maes, Bruno Lapauw, Guy Brusselle Published: 2026 ABSTRACT Obesity affects more than 650 million adults worldwide, with prevalence continuing to rise across all age groups and continents. This trend has important implications for asthma: individuals with obesity have a 30–50% higher risk of developing asthma, and obesity is highly prevalent among people with established disease. Mean body mass index in clinical trials and registries of adults with asthma consistently ranges from 28 kg·m−2 to 30 kg·m−2, with up to 70% of patients being overweight or obese. These numbers highlight obesity as one of the most common comorbidities in asthma, consistently associated with poorer asthma control and a higher risk of exacerbations. Although obesity-associated asthma is often described as type-2 (T2)-low phenotype, it is increasingly recognised as a heterogeneous condition not restricted to a single phenotype. Excess adiposity influences asthma through multiple mechanisms, including dysregulated adipokine signalling, impaired innate lymphoid cells type 2 (ILC2)–eosinophil–macrophage cross-talk in adipose tissue, systemic low-grade inflammation, metabolic dysfunction, and mechanical effects on lung volumes. This diversity complicates diagnosis, endotyping, and treatment stratification. Obesity should therefore be considered a treatable trait in asthma. Weight reduction (through lifestyle interventions, pharmacotherapy or bariatric surgery) improves symptoms, lung function, and exacerbation risk across both T2-high and T2-low asthma. Importantly, patients with obesity experience similar reductions in exacerbations with anti-T2 biologics as their lean counterparts, though improvements in symptoms and lung function are variable. Future research should prioritise randomised, placebo-controlled trials evaluating glucagon-like peptide (GLP)-1 and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-agonist therapies specifically in patients with asthma and obesity, and elucidate how obesity modifies inflammatory endotypes and treatment responses. Introduction Asthma is a heterogeneous chronic airway disease characterised by variable respiratory symptoms (i.e. dyspnoea, wheezing, cough and chest tightness), due to variable expiratory airflow limitation, airway inflammation and bronchial hyperresponsiveness. Asthma encompasses multiple clinical phenotypes, depending on the age at onset (early-onset asthma starting in childhood versus adult-onset asthma), and the presence or absence of immunoglobulin (Ig)E-mediated sensitisation to aero-allergens (e.g. house dust mite, moulds, pollen of trees and grasses, and cat or dog dander), differentiating allergic asthma from intrinsic, nonallergic eosinophilic asthma [1]. A conventional spectrum ranging from type 2 (T2)-high to T2-low inflammation provides a framework for this heterogeneity. While early-onset, allergic T2-high asthma is associated with eosinophilic inflammation and good response to inhaled corticosteroids (ICS), there are at least two other asthma phenotypes which are less responsive to ICS and are associated with worse outcomes: adult-onset, intrinsic eosinophilic asthma, often requiring add-on therapies with biologics to control the disease, and T2-low asthma, typically marked by neutrophilic or paucigranulocytic inflammation, corticosteroid resistance, and poorer outcomes, and remaining a major clinical challenge [2–4]. Over the past decade, T2-high inflammation has become the dominant focus of precision medicine in (severe) asthma [5]. The development of targeted biologics has established T2-high inflammation as the best-characterised and most successfully targeted treatable trait to date. However, this success has also highlighted the need to expand the treatable traits framework beyond airway inflammation [6]. One important comorbidity is obesity, a chronic disease characterised by excess of adiposity which results from an enduring imbalance between energy intake and expenditure. The prevalence of obesity is rapidly increasing worldwide: currently, ∼60% of European adults suffer from overweight or obesity. Obesity has been, and remains, more prevalent in women than in men: the global age-standardised prevalence increased from 8.8% (uncertainty interval 8.5–9.1%) in 1990 to 18.5% (17.9–19.1%) in 2022 in women, and from 4.8% (4.6–5.0%) to 14.0% (13.4–14.6%) in men [7]. Even more worryingly, the prevalence of overweight and obesity is rapidly increasing in children as well [7, 8]. Although body mass index (BMI) is important for defining obesity (≥30 kg·m−2), BMI alone does not always fully capture the presence of excess adiposity or its metabolic consequences. Therefore, overweight (i.e. levels of BMI between ≥25 kg·m−2 and 30 kg·m−2) should also be considered in the presence of at least one additional anthropometric criterion (e.g. increased waist circumference) [9]. There are at least two misconceptions of obesity-related asthma. Firstly, obesity has traditionally been viewed as a defining comorbidity of T2-low asthma, particularly in phenotypes characterised by neutrophilic or pauci-granulocytic inflammation. Obesity-related asthma has often been described as a separate phenotype [10, 11]. However, obesity may also play an important role in T2-high asthma, indicating that its impact is not confined to a single endotype or phenotype [8]. Secondly, in the subgroup of adults with obesity and T2-low, neutrophilic asthma, neutrophils have been considered as therapeutic targets. However, treatment strategies targeting (directly or indirectly) neutrophilic inflammation in asthma (including obesity-related asthma) have failed or even caused harm [3, 12]. In contrast, in patients with “neutrophilic” T2-low asthma, the upstream causes of neutrophilic airway inflammation (i.e. smoking, air pollution, chronic infection and/or obesity) should be addressed. In this state-of-the-art review, we provide an overview of the burden of obesity specific to adults with asthma. By combining physiology, immunology and biology, we then outline the mechanisms by which obesity impacts asthma, not only as an independent risk factor for developing asthma, but also in terms of asthma control and response to treatment in patients with established disease. Finally, we provide an overview of potential treatment strategies for people living with obesity and asthma. Burden of overweight and obesity among adults with asthma While asthma has an overall prevalence of 6–10% in Western countries, its prevalence is much higher in people with obesity [13, 14]. Data from the United States of America (2011–2014) indicated an asthma prevalence of 14.6% in people with obesity in the general population. Conversely, the prevalence of obesity is much higher in asthmatics in the USA compared to nonasthmatic controls (49.5% versus 36.1%, National Health and Nutrition Examination Survey 1999–2020) [15]. In the Rotterdam Study, a population-based prospective cohort study in middle-aged and older adults in the Netherlands, subjects with physician-diagnosed asthma had a higher prevalence of obesity (33.2% versus 18.3%; OR 2.02, 95% CI 1.66–2.47; mean BMI 28.5 kg·m−2 versus 26.8 kg·m−2) [16]. Table 1 provides an overview of landmark clinical trials in mild-to-moderate, severe and corticosteroid-dependent severe asthma. Although randomised controlled trials (RCTs) enrol selected patient populations based on pre-defined inclusion and exclusion criteria, mean BMI values in these trials consistently fall within the overweight or obese range. Mean BMI in adults with in mild-to-moderate asthma ranged between 25.9±5.6 kg·m−2 (SYGMA 1) and 27.5±6.6 kg·m−2 (Novel-START) [17–19]. In adults with severe eosinophilic asthma, mean BMI ranged between 27.6±6.2 kg·m−2 (MENSA) and 30.2±6.5 kg·m−2 (ZONDA) [20–26]. Real-life data from severe asthma registries including the International Severe Asthma registry (ISAR) and the Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) indicate similar mean BMI of ∼28 kg·m−2. In ISAR, 70.4% of all patients with severe asthma (n=4990) were overweight or obese [27]. TABLE 1Prevalence of overweight and obesity in adolescents and adults with asthmaSubjectsAge yearsFemaleBMI kg·m−2 Mild-moderate asthma RCTs Novel-START225#34.9±14.3129 (57.3)27.5±6.6 SYGMA 1383639.6±16.62345 (61.1)25.9±5.6 SYGMA 2417641.0±17.02597 (62.2)26.4±5.7 Severe asthma RCTs DREAM156#48.6±11.193 (60)28.9±5.8 MENSA194#51116 (60)27.6±6.2 SIROCCO398#47.6±14.5252 (63)28.2±6.2 CALIMA411#49.0±14.3273 (62)28.8±6.5 QUEST190247.9±15.31197 (62.9)29.2±6.8 PATHWAY412#51.3±12.4267 (64.8)28.1±5.0 NAVIGATOR105949.5±16.1672 (63.5)28.5±7.0 Corticosteroid-dependent severe asthma RCTs SIRIUS69#5044 (64)27.8±5.9 ZONDA7352.9±10.147 (64)30.2±6.5 VENTURE21051.3±12.6127 (60)29.3±6.0 SOURCE150#53.4±12.094 (63)29.4±7.0 Severe asthma registry SHARP123156.5±13.2602 (48.9)27.8±5.5 ISAR3717542305 (62.0)28.1¶Data are presented as n, mean±sd or n (%), unless otherwise stated. BMI: body mass index; RCT: randomised controlled trial; SHARP: Severe Heterogeneous Asthma Research collaboration, Patient-centred; ISAR: International Severe Asthma registry. #: no total patient characteristics were available for these studies; the characteristics for the largest intervention group are presented; ¶: data presented as median. Prevalence of overweight and obesity in adolescents and adults with asthma Data are presented as n, mean±sd or n (%), unless otherwise stated. BMI: body mass index; RCT: randomised controlled trial; SHARP: Severe Heterogeneous Asthma Research collaboration, Patient-centred; ISAR: International Severe Asthma registry. #: no total patient characteristics were available for these studies; the characteristics for the largest intervention group are presented; ¶: data presented as median. Collectively, population-based observational studies and real-world registry data demonstrate a substantial burden of overweight and obesity among adults with asthma compared with the general population. RCT data further illustrate that overweight and obesity are highly prevalent among patients with asthma (who meet trial eligibility criteria) across the spectrum of asthma severity (i.e. mild, moderate and severe asthma) and clinical phenotypes (i.e. both T2-low and T2-high asthma). Interestingly, many RCTs and registries of asthma in adulthood have a female predominance (around two-thirds), which may reflect both the higher burden of asthma in adult women and sex differences in obesity prevalence. Epidemiological evidence for obesity as an important risk factor for asthma Epidemiological studies show that obesity is a well-established risk factor for asthma development across the life course. Obesity plays a role in asthma starting during childhood: a longitudinal study from the Taiwan Children Health Study found that obesity in children was a risk factor for asthma onset (hazard ratio (HR) 1.28, 95% CI 1.05–1.56) [28], findings similar to a large-scale retrospective cohort study from the PEDSnet clinical data research network (HR 1.26, 95% CI 1.18–1.34) and the BMI Epidemiology Study in Gothenburg, Sweden (HR 1.45, 95% CI 1.00–2.11) [29, 30]. Interestingly, maternal overweight and obesity are also associated with an increased asthma risk in the offspring, indicating the contribution of epigenetics [31]. In adulthood, obesity remains an independent risk factor for the development of asthma in males and females alike [32]. Meta-analysis in 63 258 asthma patients and 1 134 131 controls yielded an overall rate ratio (RR) of 2.13 (95% CI 1.66–2.73) for asthma for high versus low BMI, and 1.32 (95% CI 1.21–1.44) per 5 kg·m−2 increase [33]. Weight gain during early adulthood further increases asthma risk later in life [34]. Beyond BMI, in adipose tissue, there are differences in the inflammatory potential of eutrophic adipocytes in lean individuals versus the hypertrophic and hyperplastic adipocytes in individuals with obesity, especially those in the visceral fat compartment [35]. Hence, combining different clinical and laboratory measures may provide better estimates of visceral adiposity dysfunction. The body roundness index has been introduced as a way to quantify body shape in a height-independent manner, and has been positively associated with asthma [36, 37]. Similar associations have been described for the visceral adipose index and the lipid accumulation product index, two alternative measures [38, 39]. More direct measures such as visceral fat area estimated via dual-energy X-ray absorptiometry total body composition analysis may further refine the assessment of adiposity-related asthma risk [40]. Genetic links between obesity and asthma susceptibility Beyond epidemiological evidence, genome-wide association studies (GWAS) have investigated a potential shared genetic aetiology between asthma and metabolic disorders, both of which are heritable traits. A positive genetic association between BMI and late-onset asthma, but not early-onset asthma, was found in a large GWAS study of the UK Biobank [41], with Mendelian randomisation providing strong evidence for a causal role of obesity with regards to an increased risk of asthma [42]. Interestingly, while childhood BMI and childhood-onset asthma share a genetic component, this is not driven by the genetic component of adult BMI [43]. GWAS also indicates a role for obesity in airway remodelling [41]. Immunology of adipose tissue in asthma pathogenesis In addition to the shared genetic risk factors that could lead to an increased susceptibility of asthma in those with obesity, the immunological potential of adipose tissue plays an important role in asthma pathogenesis. Epidemiological studies have found an association between the amount/volume of visceral adipose tissue and the risk of asthma, mainly in females and older adults [44], reflected by a higher amount of visceral adipose tissue in individuals with asthma compared to controls. Moreover, higher levels of C-reactive protein (CRP) and leptin in serum have been described in asthma patients with obesity compared to those without obesity [45]. However, while serum CRP is a well-established marker of systemic inflammation, it is unclear whether CRP is a good marker for metabolic activity in adipose tissue. In homeostatic adipose tissue, there is a balance between the anti-inflammatory adipokine adiponectin, and the pro-inflammatory leptin. Adiponectin signals though the adiponectin receptors (ADIPOR), which are not only expressed in skeletal muscle and the liver, but also on monocytes, B-cells and natural killer cells. The ADIPOR agonist AdipoRon has been associated with reduced airway inflammation in a murine model of asthma [46]. Leptin enhances production of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6, and has been implied in early effects of obesity pathogenesis. Adipose tissue in obesity is marked by elevated leptin and reduced adiponectin levels, accompanied by a switch from alternatively activated (M2) towards pro-inflammatory (M1) adipose tissue macrophages [47]. In both mice and humans, it was demonstrated that innate lymphoid cells type 2 (ILC2; key drivers of pathogenesis in late-onset eosinophilic asthma) are present in white adipose tissue and that ILC2 numbers decrease in white adipose tissue in obesity [48]. ILC2 are an important source of IL-5 and IL-13, thus modulating the attraction and function of homeostatic eosinophils in the adipose tissue. These adipose homeostatic eosinophils produce IL-4, which not only stimulates anti-inflammatory IL-10 and transforming growth factor-β release by M2 macrophages, but also decreases leptin levels (figure 1). The homeostatic role of adipose tissue eosinophils through IL-4-dependent M2 macrophage polarisation has been demonstrated in early mechanistic work by Wu et al. [49]; who also showed that eosinophil-deficient mice developed increased adiposity and insulin resistance. Accordingly, it was demonstrated that individuals with obesity, compared to lean individuals, have lower adipose eosinophil numbers and plasma IL-4 levels, accompanied by elevated leptin levels [50]. In obesity, changes in the adiponectin/leptin balance stimulate adipocytes to produce IL-6, TNF-α and monocyte chemoattractant protein (MCP)-1, leading to increased systemic levels that may contribute to airway inflammation in asthma (figure 1). Peters et al. [51] found that plasma IL-6 levels are indeed associated with severe asthma, metabolic dysfunction and obesity. In a population-based cohort, IL-6 plasma levels were associated with overweight/obese nonallergic asthma, but not with overweight/obese (or lean) allergic asthma [52]. Moreover, a unique panel of systemic inflammation-related proteins was identified, specifically associated with overweight/obese asthma, including CC motif chemokine ligand 20, fibroblast growth factor 19, IL-5 and TNF ligand superfamily 9 [52]. Serum levels of TNF-α are elevated in obesity [53] and a population-based study demonstrated that obesity is stronger associated with asthma in subjects with specific polymorphisms in the human TNF-α gene, indicative of an interaction between obesity, TNF-α and asthma [54]. However, in a placebo-controlled trial, treatment with golimumab, a monoclonal antibody targeting TNF-α, in patients with uncontrolled moderate-to-severe asthma did not improve exacerbation rates or lung function, and was associated with an increased risk of adverse events such as lower respiratory tract infections [55]. Overview of homeostatic adipose tissue (green background), pro-inflammatory pathways in adipose tissue induced by obesity (red background), and their relevance in the context of asthma. FENO: exhaled nitric oxide fraction; iNOS: inducible nitric oxide synthase; IL: interleukin; TSLP: thymic stromal lymphopoetin; CXCL-8: chemokine (C-X-C motif) ligand 8; DAMP: damage-associated molecular pattern; Th2: T-helper 2; ILC2: innate lymphoid cell type-2; Ig: immunoglobulin; IFN: interferon; TNF: tumour necrosis factor; M1: pro-inflammatory macrophage; NLRP: nucleotide oligomerisation domain-receptor protein; M2: alternatively activated macrophage; TGF: transforming growth factor; MCP: monocyte chemoattractant protein. Created with Biorender. The IL-17/IL-23 axis is upregulated in obesity (especially in women [56]) and in asthma [57]. While early clinical data are limited, increased IL-17F has been reported in asthma and obesity in parallel with in vitro work showing that IL-17A/F drives glucocorticoid receptor (GR)-α/GR-β dysregulation in obese adipocytes [58]. Defects in GR-α with dysregulation of GR-α/GR-β ratio is a known mechanism of resistance to glucocorticoids in severe asthma. Obesity-related changes in steroid metabolism relevant to asthma Because glucocorticoids and sex steroids share precursors, biosynthetic enzymes, and regulatory pathways within adipose tissue, obesity-driven shifts in steroid metabolism that impair glucocorticoid signalling may simultaneously perturb sex-steroid balance in ways that may influence asthma risk. Population-based studies show lower odds of asthma in women with obesity and higher free serum testosterone and oestradiol [59, 60], suggesting a protective role of androgens that may be counteracted by obesity-related metabolic and inflammatory changes. Visceral adipose tissue is indeed a major site of aromatase-mediated conversion of androgens to oestrogens, showing particularly high aromatase activity compared with subcutaneous fat, and thus potentially increasing oestrogen exposure while limiting systemic testosterone. In the context of asthma, oestrogens have been associated with enhanced T2-inflammation, whereas testosterone appears to have protective effects [61]. Indeed, ILC2 express androgen and oestrogen receptors; whereas testosterone has been shown to decrease the production of type 2 cytokines by ILC2, oestrogens stimulate type 2 cytokine production by ILC2, implicating a sexual dimorphism. Together, these systemic cytokine shifts and hormone-linked immunomodulatory changes may amplify innate immune activation, also reflected by elevated circulating MCP-1, CXCL-8, and the damage associated molecular patterns (DAMPs) HMGB1 and Hsp72, which are further increased in obese asthma and reach highest levels in severe disease [62]. This raises the possibility that airway-resident cells already expressing cognate receptors such as CCR2 and CXCR1/2 are exposed to higher ligand concentrations systemically. Airway immune dysregulation due to obesity In the airways, human studies have demonstrated increased expression of IL-1β and increased nucleotide oligomerisation domain-receptor protein 3 (NLRP3) and NOD1 in sputum from patients with asthma and obesity. Several candidate DAMPs relevant to asthma (HMGB1 and its receptor RAGE, and HSP70/Hsp72) have also been identified in airway samples. They are increased in induced sputum in asthma where they associate with disease activity and neutrophilic inflammation [63, 64]. In the context of obesity, metabolic danger signals may provide additional activation to these pathways, although their direct role as upstream activators of airway inflammation in obesity-associated asthma has not been demonstrated. Wood et al. [65] demonstrated increased expression of IL-1β as well as of nucleotide oligomerisation domain-receptor protein 3 (NLRP3) and nucleotide oligomerisation domain 1 (NOD1) in sputum of patients with asthma and obesity compared to asthma patients without obesity, although neutrophil numbers were not significantly elevated. Interestingly, intake of saturated fatty acids in asthma patients without obesity increased sputum neutrophil numbers and sputum expression levels of Toll-like receptor 4 and NLRP3, suggestive that high fat intake can cause increased inflammatory responses in asthma. Pro-inflammatory cascades in macrophages, which cause IL-1β, TNFα and IL-6 release, not only promote neutrophil recruitment, but also act on Th17 lymphocytes and innate lymphoid cells type 3 (ILC3), thus indirectly perpetuating the neutrophil response and contributing to bronchoconstriction. Although these mechanisms remain to be validated in humans, the involvement of both IL-17 producing ILC (ILC3) and the NLRP3 inflammasome has been demonstrated in a murine model of obese asthma [66]. Obesity-associated asthma is however not always characterised by neutrophilia. Todd et al. [67] found no differences between sputum neutrophil (and eosinophil) count in obese and non-obese asthma, whereas others found only elevated neutrophil numbers in blood, specifically in female patients [68]. Notably, in individuals without asthma but with obesity, there are indications of increased airway inflammation, with elevated expression of IL-6, chemokine (C-X-C motif) ligand (CXCL)8 and IL-17 in induced sputum [69]. A recent study demonstrated that obesity itself is characterised by a specific sputum microbiome and cytokine mediator expression, which is different from obesity with asthma, suggesting that the microbes in the airways may affect the disease mechanisms in obese asthma [70]. Marijsse et al. [71] demonstrated that individuals with asthma and obesity have high IL-5/IL-17A/IL-25 mRNA expression in sputum, suggesting the presence of a mixed inflammatory profile. In this study, IL-17 mRNA levels correlated with BMI, and people with obesity and asthma had elevated sputum neutrophil numbers. Notably, sputum IL-5 mRNA and protein levels also correlated significantly with BMI in people with asthma [71, 72] and submucosal eosinophil numbers were elevated in severe obese asthma [72]. This increased tissue retention of eosinophils in the airways is potentially linked to elevated TNF-α and reduced surfactant protein (SP)-A levels in obese asthma, as demonstrated in a mechanistic study [73]. However, sputum eosinophil numbers do not differ between asthma patients with and without obesity [71, 72, 74], implicating that the impact of eosinophilic airway inflammation and its involvement in exacerbations in obese asthma may be underestimated. Other typical T2 markers, such as IL-4 and IL-13 mRNA in sputum did not show significant differences between asthma patients with and without obesity [71]. However, nasal allergen challenge induced a higher release of the T2-promoting cytokine IL-33 and of IL-13 into the nasal lumen in patients with asthma and obesity compared to lean asthma patients, probably due to activation of the NADPH oxidase enzyme DUOX1 [75]. In summary, these studies underscore that obesity modifies asthma not just by shifting inflammation towards a single endotype, but by superimposing systemic metabolic and adipose-derived inflammatory signals onto pre-existing airway immune pathways. This is further supported by comparable serum adipokine profiles in patients with obesity and T2-high asthma compared to those with T2-low asthma [76]. Systemically, people with obesity and asthma tend to exhibit higher circulating neutrophil counts [77], alongside elevated levels of leptin and pro-inflammatory cytokines such as IL-6, TNF-α, and MCP-1. Conversely, classical T2-biomarkers (blood eosinophils, exhaled nitric oxide fraction (FENO), and total IgE) are generally independent of BMI, suggesting that obesity does not attenuate systemic T2-signalling in a uniform manner [78, 79]. Moreover, obesity may even potentiate T2-responses through adipose-derived mediators such as leptin, which can enhance IL-13 production [80]. Within the airways, these systemic shifts converge with local mechanisms such as inflammasome activation, IL-17/IL-23 pathway upregulation, altered steroid signalling, and adipose-driven cytokine gradients, resulting in highly variable inflammatory phenotypes that range from neutrophilic to mixed eosinophilic-neutrophilic patterns, encompassing the entire spectrum of T2-inflammation. The mechanisms described do not exclusively act during asthma development, but continue to modulate asthma control and exacerbation risk throughout the disease course. In individuals with established asthma, obesity-related systemic inflammation, altered steroid signalling, and airway immune dysregulation interact with physiological constraints and comorbid conditions described in the next section, thereby amplifying symptom burden and susceptibility to asthma attacks. Functional and physiological consequences of obesity in asthma Obesity is consistently associated with higher symptom burden, worse asthma control, and more frequent exacerbations, despite similar lung function compared with individuals without obesity [81, 82]. In the Respiratory Health in Northern Europe (RHINE) III survey, general (BMI ≥30.0 kg·m−2) and abdominal (waist circumference ≥102 cm in males and ≥88 cm in females) obesity were independently associated with wheeze, night-time cough, and night-time chest tightness [83]. In a United Kingdom cohort of 200 patients admitted for asthma exacerbations, almost two-thirds of patients were obese (63.6% of frequent exacerbators and 63.4% of infrequent exacerbators) [84]. In the general United States population, obesity was the strongest predictor for severe asthma exacerbations (OR 1.67, 95% CI 1.24–2.26) [85]. In particular, the combination of obesity and blood neutrophilia has been associated with uncontrolled asthma [78]. While individuals with asthma and obesity experience worse clinical outcomes, there is no evidence of a proportional increase in asthma-related mortality. However, obesity is associated with an increased risk of all-cause and cardiovascular mortality [86]. In the nationwide registry-based cohort study NORDSTAR (NORdic Dataset for aSThma Research), severe asthma has been associated with a higher all-cause mortality as compared with mild-to-moderate asthma (HR 1.99, 95% CI 1.90–2.09) [87]. The mortality hazard ratio attenuated after adjustment for oral corticosteroid (OCS) use (HR 1.30) and T2 inflammatory markers (HR 1.34); whether adjusting for BMI would attenuate the increased hazard ratio for all-cause and disease-specific mortality (i.e. respiratory, cardiovascular and cancer-related mortality) has not been reported. Physiological changes resulting from obesity further contribute to poor asthma control. Children with obesity are at higher risk of airway dysanapsis, i.e. disproportionate lung growth which produces airflow limitation, by decreasing the ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) [88]. Obesity has also been associated with significantly reduced FEV1 and FVC in adults [89]. Excess adiposity reduces functional residual capacity, promotes airway collapse, increases the perception of dyspnoea, and alters breathing patterns, all of which can amplify asthma symptoms even in the case of preserved FEV1 [90]. Impulse oscillometry, an effort-independent noninvasive pulmonary function test that measures airway resistance and lung reactance, provides additional insights into these physiological abnormalities. Compared to spirometry, oscillometry more sensitively detects small-airway dysfunction, correlates better with symptom burden, and more accurately reflects poor asthma control [91, 92]. Higher BMI has been associated with worse airway resistance and reactance measured by oscillometry in patients with moderate-to-severe asthma, despite preserved FEV1 and FVC, supporting the concept of obesity-related small airway dysfunction [93]. Increased BMI (i.e. overweight and obesity) is particularly present in individuals with late-onset asthma. This phenotype has also been associated with a higher prevalence of comorbidities compared to nonasthmatic controls, including diabetes, osteoporosis, gastro-oesophageal reflux disease (GORD), obstructive sleep apnoea, and depression [94]. These obesity-related comorbidities in turn contribute to worse asthma control and an increased risk of asthma attacks (figure 2) [95]. Treatment with OCS, either as bursts for acute asthma attacks or as maintenance treatment in corticodependent uncontrolled severe asthma, further aggravates obesity and its multimorbidity, implicating a vicious circle. Moreover, patients with asthma and obesity engage less in physical activity compared to patients with normal weight, which further contributes to deconditioning [96]. Interestingly, the presence of asthma has been associated with a higher risk of obesity irrespective of physical activity (relative risk 1.22), especially in asthma patients treated with OCS (1.99 for OCS users versus 1.15 in asthma patients not using OCS) [97]. Obesity is associated with uncontrolled and/or severe asthma, leading to a vicious circle of asthma attacks, treated with systemic corticosteroids, which aggravate obesity and its comorbidities and increase the future risk of asthma attacks. IL: interleukin; TNF: tumour necrosis factor; MCP: monocyte chemoattractant protein; ICS: inhaled corticosteroid; GR: glucocorticoid receptor; T2: type 2. Created with Biorender. Treatment response in people with asthma and obesity Patients with severe asthma and obesity should be managed for asthma according to the same principles as patients without obesity. In patients who do not achieve a satisfactory reduction in BMI despite weight-loss interventions, it is important to evaluate the effectiveness of maintenance asthma treatment. Obesity impacts treatment responses, which in turn paradoxically leads to higher use of short-acting β2-agonists (SABA) and OCS [98]. Although SABA and OCS are important acute treatments of severe acute asthma attacks during emergency department visits or hospital admissions, these should not be used in the long-term management of asthma because of their serious adverse events and complications. With regards to ICS, a reduced response to ICS and ICS/long-acting β2-agonists in asthma patients with obesity has been described [68, 99–102]. Importantly, obesity-related asthma also encompasses patients with evidence of T2-high inflammation (e.g. increased sputum eosinophils, increased blood eosinophil count or elevated FENO), who typically show a good response to ICS [103]. The response to ICS in patients with asthma and obesity therefore depends on the absence or presence of T2-inflammation, rather than the presence of obesity [104]. Conversely, for muscarinic antagonists, effectiveness in asthma patients with obesity has been inconclusive, although the high mean BMI (31.4 kg·m−2) in a particular study group suggests effectiveness in patients with obesity [105]. For the anti-T2 biologics, there are differences in the magnitude of benefit based on the drug and outcome investigated. Observational studies of omalizumab show conflicting results: some series reported smaller reductions in exacerbations and smaller gains in FEV1 or asthma control with higher BMI [106–111], while others reported greater or no differences in lung function, asthma control, or exacerbations across BMI categories [106–113]. For dupilumab, post hoc analyses found no interaction between BMI and dupilumab efficacy for exacerbation reduction or FEV1 improvements [114, 115], although a small prospective real-world cohort suggested that obesity was associated with markedly lower odds of clinical remission [116]. Anti-IL-5 drugs show a consistent effect on exacerbation reduction regardless of BMI category, and similar improvements in asthma control (Asthma Control Questionnaire (ACQ)-5) across groups. FEV1 gains were smaller in the subgroup with obesity in some analyses [20, 21, 117–120]. Observational studies largely support mepolizumab effectiveness in patients with obesity [121–125], but several clinical cohorts identified a lower likelihood of “super-response” or improvement in asthma control among those with higher BMI [124, 125]. Pooled analyses of reslizumab and benralizumab trials suggest reductions in exacerbations with treatment across BMI groups, although some subgroup analyses (benralizumab) indicated attenuated FEV1 or exacerbation benefits at very high BMI thresholds (>35 kg·m−2) [22, 23, 126, 127]. Pooled analyses of tezepelumab trials demonstrated consistent, significant reductions in exacerbations and hospitalisations across BMI categories, suggesting BMI has limited impact on tezepelumab efficacy in trial populations [25, 128–130]. Overall, anti-T2 biologics remain effective in reducing attacks in T2-high asthma patients with obesity, but their benefit on patient reported outcomes such as asthma control and quality of life is often attenuated. This dissociation between exacerbation reduction and persistent symptom burden probably reflects the substantial noninflammatory contributions of obesity, including increased mechanical load, deconditioning and obesity-related comorbidities such as GORD, rather than insufficient suppression of the targeted pathway. This also affects the likelihood of achieving clinical remission in patients with severe asthma upon biologic treatment, since long-term well-controlled asthma (using ACQ or Asthma Control Test scores) is a key criterium of clinical remission. Moreover, evidence is heterogeneous and currently limited to post hoc analyses and retrospective studies [131]. Anti-T2 biologics reduce exacerbations in patients with severe asthma across BMI categories, but improvements in lung function and symptom control may be more variable in asthma patients with obesity [132]. Further large, adjusted or stratified real-world analyses are needed to clarify whether differences exist in effectiveness of anti-T2 biologics. Treatment options for obesity in people with asthma Obesity management is always a multimodal approach where lifestyle modifications are the cornerstone of treatment. The primary goal is to achieve a negative energy balance that enables weight loss. To accomplish this, specific and individualised recommendations regarding diet and exercise should be provided. It is equally important to determine the intended weight loss through shared decision-making, taking into account the presence and severity of comorbidities [133]. To have a significant impact on asthma outcomes, a weight loss of ≥5% has been proposed [134]. In cases of co-existing comorbidities such as obstructive sleep apnoea, a greater amount of weight loss is needed. Diet and physical activity (average weight loss 0–5%) From a general principle, the caloric intake should decrease and the energy expenditure must increase. Importantly, physical activity by itself has been shown to improve asthma symptom scores and respiratory symptoms, independently of weight loss [135, 136]. One small RCT of a 16-week Counterweight-Plus programme (consisting of an 800 kcal per day low-energy formula) in adults with difficult-to-treat asthma and obesity showed greater weight loss in the intervention group, as well as greater improvements in asthma control and quality of life (ACQ-6 and Asthma Quality of Life Questionnaire scores, respectively) [137]. These findings highlight the importance of addressing both the dietary habits and the sedentary lifestyle using structured programmes such as in pulmonary rehabilitation. If insufficient weight loss is achieved through dietary and behavioural changes, escalation to pharmacological or surgical treatment of obesity is necessary (figure 3). The Finnish Seinäjoki Adult Asthma Study has shown that 86% of asthma patients with obesity remained obese after 12 years of follow-up, indicating the challenging nature of weight-loss interventions [82]. Treatment options for obesity in people with asthma. GLP: glucagon-like peptide; GIP: glucose-dependent insulinotropic polypeptide. Created with Biorender. Bariatric/metabolic surgery (average weight loss >20%) The two most common bariatric surgery procedures are Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy. Both types of surgery physically reduce the stomach size and result in altered endogenous gut hormone signalling (including glucagon-like peptide (GLP)-1) influencing the gut–brain axis, leading together to higher satiety and reduced appetite. These surgical procedures have been shown to restore the adiponectin/leptin ratio in a small cohort study, while in vitro corticosteroid response (response to dexamethasone in peripheral blood mononuclear cells) was improved in these patients [138]. In addition, the gut microbiota is rapidly altered after bariatric surgery, particularly after RYGB. These alterations in gut microbiota after bariatric surgery may ameliorate the asthma control on top of the weight loss, by increasing the production of short-chain fatty acids, e.g. propionate, acetate and butyrate, which are associated with anti-inflammatory effects [139] and may contribute to restoring a tolerogenic environment in the gut and airways through the gut–lung axis [140, 141]. In patients with asthma, bariatric surgery not only reduces the use of asthma medication, but also the risk of hospital admission or emergency department attendance due to asthma attacks by >50% [134, 142, 143]. A meta-analysis of 15 studies found that 54% of asthmatics were able to completely stop asthma medication post-metabolic surgery [144]. Several small prospective studies have shown that the positive effect of bariatric surgery on lung function and asthma control remained clinically stable during a follow-up of 5–8 years, suggesting a sustained response [145, 146]. Of course, weight loss maintenance is important to sustain the beneficial effects of bariatric surgery on asthma control. In contrast, the persistence of the metabolic syndrome after bariatric surgery has been associated with less favourable results regarding asthma control [147]. When obesity-related asthma remains poorly controlled despite optimised standard asthma therapy and structured weight-loss interventions, bariatric surgery should be considered within a comprehensive management strategy. Indeed, among patients living with obesity who meet eligibility criteria for bariatric surgery, persistently poor asthma control should not be regarded as a contraindication. Instead, it should be considered a clinically relevant comorbidity that favours consideration for surgery, given the substantial and durable improvements in asthma outcomes after surgery. Anti-obesity medications: GLP1-analogues and dual GLP-1/GIP receptor agonists (average weight loss 15–20%) GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are gut hormones released by L- and K-enteroendocrine cells, respectively, in the small intestine in response to a meal. GLP-1 and GIP induce satiety, slow gastric emptying and stimulate insulin secretion. GLP-1 exerts its effect by binding to the GLP-1 receptor, which is expressed abundantly throughout the body, including the lungs where GLP binding to the GLP-1 receptor stimulates vasodilation, surfactant production and bronchodilatation. GLP-1 also has anti-inflammatory properties by restoring protein kinase A activity, a known inhibitor of the NF-κB signalling pathway [148, 149]. Nowadays, weight loss achieved with GLP-1 receptor agonists and dual GLP-1/GIP analogues is comparable with weight loss following bariatric surgery. Intriguingly, a key question is whether the GLP-1 analogues provide additional benefits for asthma control independently of their effects on weight loss. The clinical data on GLP-1 analogues are largely retrospective and were derived from patients with asthma and type 2 diabetes. An important consideration therein, is that dosages of GLP-1 analogues used for type 2 diabetes are lower than those prescribed for obesity. Additionally, it is also well established that the amount of weight loss is lower in patients with both obesity and type 2 diabetes, emphasising the need for specific clinical trials that investigate the effect of GLP-1 analogues in people with asthma and obesity. To our knowledge, there is only one phase II trial ongoing with semaglutide 2.4 mg once weekly in obese patients without diabetes and symptomatic asthma in the United States (GATA-3; clinicaltrials.com identifier NCT05254314). Results from this trial are expected in 2026. Overall weight loss achieved with semaglutide 2.4 mg s.c. once weekly is ∼15% [150]. Dual GLP-1/GIP receptor agonists, like tirzepatide, have shown utility in the treatment of obesity as well as moderate-to-severe obstructive sleep apnoea and obesity [19]. Mean weight loss achieved with tirzepatide in the highest dosage (15 mg s.c. once weekly) is ∼20% [151]. Extrapolating the results of weight loss from clinical obesity trials towards patients with asthma is challenging. Patients with uncontrolled severe asthma often require (acute or maintenance) treatment with systemic corticosteroids, which generally is an exclusion criterion in obesity trials. Recently, an observational real-world study in the UK including people with asthma and obesity, showed that the use of GLP-1 analogues was associated with greater weight loss and a better overall asthma control score compared to age-, sex- and exacerbation-matched controls with asthma and obesity who did not receive treatment with GLP-1 analogues. However, there was no significant effect on exacerbations [152]. An additional clinical consideration is that GORD is highly prevalent in patients with asthma and obesity, and GLP-1 receptor agonists commonly delay gastric emptying and cause gastrointestinal side effects such as nausea, particularly during treatment initiation [150, 153, 154]. These effects may exacerbate or mimic reflux-related respiratory symptoms, including cough, chest discomfort or dyspnoea, potentially confounding early assessments of asthma control [155]. Future directions Future research in obesity-related asthma should refocus from targeting downstream inflammatory pathways toward addressing obesity itself as the primary disease modifier. Recent studies targeting neutrophilic inflammation or IL-6 signalling in asthma suggest that intervening on obesity-induced inflammation in isolation may be insufficient, reinforcing a “back-to-basics” approach in which the root cause, namely excess adiposity and metabolic dysfunction, should be treated. In this context, modern anti-obesity therapies, particularly GLP-1 receptor agonists and dual GLP-1/GIP agonists, represent a promising therapeutic avenue. Randomised, placebo-controlled trials in patients with asthma and obesity are now needed to determine whether these agents improve asthma outcomes, and to disentangle weight-loss-dependent effects from potential direct pulmonary or immunomodulatory mechanisms. In parallel, it remains unclear whether obesity modifies the prognostic and predictive value of established T2 inflammatory biomarkers, including blood eosinophil count and FENO. Prospective studies should therefore investigate how obesity and metabolic dysfunction influence these T2 biomarkers, and whether complementary markers of metabolic health or visceral adiposity can improve risk stratification and prediction of treatment response in asthma. Finally, future biologic trials in severe asthma should prospectively account for obesity-related symptom burden, comorbidities, and nonasthma drivers of poor patient-reported outcomes when defining treatment response and clinical remission, as failure to do so may underestimate therapeutic benefit in this increasingly prevalent patient population. Conclusion In conclusion, epidemiologic, genetic and clinical evidence has demonstrated that obesity is not only an independent risk factor for developing asthma, but also aggravates symptoms and increases the risk of future attacks in patients with established disease. Importantly, these data challenge two persistent misconceptions in obesity-related asthma. First, obesity should not be viewed as a defining feature of a distinct, predominantly T2-low asthma phenotype, as its adverse effects extend across inflammatory endotypes, including T2-high disease. Second, the limited success and potential harm of therapies targeting neutrophilic inflammation underscore that neutrophils are unlikely to represent an appropriate primary therapeutic target in obesity-related asthma; instead, upstream drivers such as obesity itself should be addressed. Accordingly, obesity itself should be considered as a treatable trait in asthma: weight reduction by lifestyle interventions, with pharmacotherapy or surgery as additional treatment strategies tailored to the individual patient's needs, has been shown to improve respiratory outcomes. Historically, obesity management relied on lifestyle interventions, with bariatric surgery reserved for severe disease. The development of GLP-1 and dual GLP-1/GIP agonists has fundamentally changed obesity treatment. Mechanistic insights suggest that additional benefit could be achieved by combining strategies which induce weight loss with therapies that target adipose-driven systemic and airway inflammation. Currently, clinical trials targeting obesity-related inflammatory pathways in asthma are ongoing. Now, there is a clear need for randomised placebo-controlled trials investigating the efficacy and safety of GLP-1 and GLP-1/GIP analogues in people with obesity and uncontrolled severe asthma.